MedTrace Logo

Effects of N-acetylcysteine on Low T3 Syndrome

NCT01501110 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2015-03-31

Study results available
· View outcomes & findings →

Summary

The propose of this study is to determine whether N-acetylcysteine is effective in reversing the changes in thyroid hormones seen in critical illness, known as the low T3 syndrome.

Conditions

  • Acute Myocardial Infarction
  • Euthyroid Sick Syndrome
  • Ischemic Heart Disease

Interventions

DRUG

N-acetylcysteine

in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    collaborator OTHER

  • Programa de pós-graduação em endocrinologia

    collaborator UNKNOWN

  • Federal University of Rio Grande do Sul

    lead OTHER

Principal Investigators

  • Josi Vidart · Federal University of Rio Grande do Sul

  • Ana maia · Federal University of Rio Grande do Sul

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-07-31
Completion
2013-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501110 on ClinicalTrials.gov